FIELD: medicine.
SUBSTANCE: inhalation formulation in the form of aerosol for treating bronchial asthma and chronic obstructive pulmonary disease containing ipratropium bromide monohydrate as an active ingredient, ethanol absolute as a solvent, an aerosol particle size regulator as an adjuvant consisting of triethyl citrate and an acid specified in a group: citric acid, hydrochloric acid, orthophosphoric acid, 1,1,1,4-tetrafluoroethane (HFA-134a) and/or 1,1,1,2,3,3,3-heptafluoropropane (HFA-227ea) as a propellant in certain proportions.
EFFECT: increasing the respirable fraction and obtaining an optimised particle size distribution profile.
7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINED AEROSOL PREPARATION FOR TREATING RESPIRATORY DISEASES | 2013 |
|
RU2536253C1 |
| AEROSOL PREPARATION BASED ON FENOTEROL HYDROBROMIDE FOR TREATING RESPIRATORY DISEASES | 2015 |
|
RU2577289C1 |
| INHALATION FORMULATION IN FORM OF AEROSOL FOR TREATING BRONCHIAL ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 2012 |
|
RU2504402C1 |
| AEROSOL COMBINATION OF SALMETEROL AND FLUTICASONE FOR TREATING RESPIRATORY DISEASES | 2013 |
|
RU2521975C1 |
| PHARMACEUTICAL AEROSOL COMPOSITION | 2009 |
|
RU2565438C2 |
| IPRATROPIUM BROMIDE SOLUTION | 2012 |
|
RU2496477C1 |
| TROVENTOL-BASED COMPOSITION | 2006 |
|
RU2457832C2 |
| PHARMACEUTICAL COMPOSITION OF METERED AEROSOLS CONTAINING ANTIASTHMATIC AGENTS IN FORM OF SUSPENSIONS, SOLUTIONS, EMULSIONS, SOLUTIONS AND EMULSIONS | 2007 |
|
RU2356537C2 |
| METHOD AND SYSTEM FOR MDI ELECTRONIC MODEL (DOSING INHALANT DEVICE) | 2012 |
|
RU2633269C2 |
| STABLE COMBINED SOLUTION OF FENOTEROL HYDROBROMIDE AND IPRATROPIUM BROMIDE | 2012 |
|
RU2493827C1 |
